Each December, many magazines deliver their obligatory summing-up issues of the highs and lows of the past twelve months. Time names its person of the year, Rolling Stone names the best songs of the year, et cetera, et cetera. It’s also an occasion that allows science, which often takes a back seat to politics and business, to shine.
There’s something far more intriguing about the best scientific discoveries and inventions of the year than, say, the best political maneuver, stock trade, or merger. But statistics suggest that many Americans are still unfamiliar, and even uncomfortable, with science; so highlighting the best of the best seems a palatable way to sum up what the people in lab coats have done for us lately. Deciding what to single out from the past year is a subjective process, often based on criteria known only to the people choosing, and this year, magazines had some differing opinions about what it means to excel in science.
Yesterday, Science named its Breakthrough of the Year for 2007 - “human genetic variation” -for a number of studies on DNA sequencing. This year, Craig Venter sequenced the first entire human genome (his own), and many other discoveries by other scientists expanded our knowledge of the links between genes and particular traits and diseases. Writing for the editors, Elizabeth Pennisi deftly and intelligently describes the field’s import:
The potential to discover what contributes to red hair, freckles, pudginess or a love of chocolate - let alone quantifying one’s genetic risk for cancer, asthma or diabetes - is both exhilarating and terrifying. It comes not only with great promise for improving health through personalized medicine … but also with risks for discrimination and loss of privacy.
Pennisi’s piece doesn’t delve into specifics, such as who helped create the charting system for scientists to track genes involved in complex diseases, or which exact studies best explained the intricacies of human genomes. But given that during the past year more than 400 U.S. newspaper articles highlighted this type of research, the broad overview is understandable. (It is interesting to note, too, that the number of genome-sequencing newspaper articles in 2007 is perhaps only half the number that focused on embryonic stem cell research, though the variety of articles published on the latter makes it more difficult to measure. There have been roughly 200 articles related to the announcement in November that scientists had turned human skin cells into what amount to embryonic stem cells, which Science named first runner-up Breakthrough of the Year.)
One group that Pennisi does highlight in her article about genome sequencing, the Wellcome Trust, also got a nod from Scientific American. The trust, which is based in the U.K., is the world’s second-largest medical charity. The editors named the group’s Case Control Consortium its Research Leader of the Year for a report it released in June linking variations (or expressions) of specific genes to increased risk for certain diseases. The trust, however, is only one of the SciAm 50.
Scientific American honored Amyris Biotechnologies as its Business Leader of the Year for its work on biofuel derived from yeast genomes; and it named the X Prize Foundation its Policy Leader of the Year for its innovative approach - contest money and notoriety - to spurring R&D projects on such things as making space travel safe and accessible. In addition to the three leaders, SciAm tipped its hat to forty-seven other standout individuals and businesses of the year. All are meritorious, certainly; unfortunately, with such a large group, a few hidden jewels-studies of cordless electric power, renewable fuels, a human form of mad cow disease -are bound to get lost. Deeper coverage of fewer winners would give the article more impact.